Repare Therapeutics (RPTX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Repare Therapeutics, a precision oncology company, has reported its Q2 2024 financial results while progressing with clinical trials, including the MYTHIC trial for ovarian and endometrial cancers. The FDA granted Fast Track designation for their drug lunresertib, and initial Phase 1 data for gastrointestinal cancer treatment was positively received. The company is also preparing for a potential registrational trial in 2025, and welcomed Dr. Steven H. Stein to their Board of Directors.
For further insights into RPTX stock, check out TipRanks’ Stock Analysis page.
